Intravesical treatment of bladder pain syndrome/interstitial cystitis: From the conventional regimens to the novel botulinum toxin injections

Expert Opinion on Investigational Drugs

Volumn 23, Issue 6, 2014, Pages 751-757

  Dellis, Athanasios ^a,b   Papatsoris, Athanasios G ^b,c  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

Bladder pain syndrome; Botulinum toxin; Detrusor; Incontinence; Injection; Interstitial cystitis; Intravesical therapy; Onabotulinumtoxin A

Indexed keywords

BOTULINUM TOXIN; CHONDROITIN SULFATE; DIMETHYL SULFOXIDE; GM 0111; HEPARIN; HYALURONIC ACID; LIDOCAINE; PENTOSAN POLYSULFATE; UNCLASSIFIED DRUG;

CONSENSUS; DRUG EFFICACY; DRUG INSTILLATION; DRUG SAFETY; HUMAN; INJECTION SITE; INTERSTITIAL CYSTITIS; PATHOPHYSIOLOGY; REVIEW; TREATMENT OUTCOME; ANIMAL; BLADDER; CYSTITIS, INTERSTITIAL; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; INTRAVESICAL DRUG ADMINISTRATION; PAIN; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADMINISTRATION, INTRAVESICAL; ANIMALS; BOTULINUM TOXINS; CLINICAL TRIALS, PHASE III AS TOPIC; CYSTITIS, INTERSTITIAL; DOUBLE-BLIND METHOD; HUMANS; PAIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; URINARY BLADDER;

EID: 84900824470     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2014.909406     Document Type: Review

References (53)

1. van de Merwe JP, Nordling J, Bouchelouche P, et al. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. Eur Urol 2008;53:60-7
2. Engeler D, Baranowski AP, Borovicka J, et al. Members of the European Association of Urology (EAU) Guidelines Office. Guidelines on chronic pelvic pain. In EAU guidelines, edition presented at the 28th EAU Annual Congress; Milan; 2013. ISBN 978-90-79754-71-7
3. Clemens JQ, Meenan RT, Rosetti MC, et al. Costs of interstitial cystitis in a managed care population. Urology 2008;71:776-80
4. van de Merwe JP, Nordling J, Bouchelouche P, et al. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. Eur Urol 2008;53:60-7
5. Hunner GL. A rare type of bladder ulcer in women: report of cases. Boston Med Surg J 1915;172:660-4
6. Warren JW, Brown V, Jacobs S, et al. Urinary tract infection and inflammation at onset of interstitial cystitis/painful bladder syndrome. Urology 2008;71:1085-90
7. Richter B, Roslind A, Hesse U, et al. YKL-40 and mast cells are associated with detrusor fibrosis in patients diagnosed with bladder pain syndrome/interstitial cystitis according to the 2008 criteria of the European Society for the Study of Interstitial Cystitis. Histopathology 2010;57:371-83
8. Parsons CL, Lilly JD, Stein P. Epithelial dysfunction in nonbacterial cystitis (interstitial cystitis). J Urol 1991;145:732-5
9. Harrington DS, Fall M, Johansson SL. Interstitial cystitis: bladder mucosa lymphocyte immunophenotyping and peripheral blood flow cytometry analysis. J Urol 1990;144:868-71
10. Hsu CC, Chuang YC, Chancellor MB. Intravesical drug delivery for dysfunctional bladder. Int J Urol 2013;20:552-62
11. Henry R, Patterson L, Avery N, et al. Absorption of alkalized intravesical lidocaine in normal and inflamed bladders: a simple method for improving bladder anaesthesia. J Urol 2001;165:1900-3
12. Nickel JC, Moldwin R, Lee S, et al. Intravesical alkalinized lidocaine (PSD597) offers sustained relief from symptoms of interstitial cystitis and painful bladder syndrome. BJU Int 2009;103:910-18
13. Baykal K, Senkul T, Sen B, et al. Intravesical heparin and peripheral neuromodulation on interstitial cystitis. Urol Int 2005;74:361-4
14. Nomiya A, Naruse T, Niimi A, et al. On-And post-treatment symptom relief by repeated instillations of heparin and alkalized lidocaine in interstitial cystitis. Int J Urol 2013;20:1118-22
15. Bade JJ, Laseur M, Nieuwenburg A, et al. A placebo-controlled study intravesical pentosanpolysulphate for the treatment of interstitial cystitis. Br J Urol 1997;79:168-71
16. Nordling J, Jorgensen S, Kallestrup E. Cystistat for the treatment of interstitial cystitis: a 3-year followup study. Urology 2001;57(6 Suppl 1):123
17. Kallestrup EB, Jorgensen S, Nordling J, et al. Treatment of interstitial cystitis with Cystistat: a hyaluronic acid product. Scand J Urol Nephrol 2005;39:143-7
18. Lee WY, Savage JR, Zhang J, et al. Prevention of anti-microbial peptide LL-37-induced apoptosis and ATP release in the urinary bladder by a modified glycosaminoglycan. PLoS One 2013;8(10):e77854
19. Nickel JC, Egerdie RB, Steinhoff G, et al. A multicenter, randomized, double-blind, parallel group pilot evaluation of the efficacy and safety of intravesical sodium chondroitin sulfate versus vehicle control in patients with interstitial cystitis/painful bladder syndrome. Urology 2010;76:804-9
20. Rossberger J, Fall M, Peeker R. Critical appraisal of dimethyl sulfoxide treatment for interstitial cystitis: discomfort, side-effects and treatment outcome. Scand J Urol Nephrol 2005;39:73-7
21. Mangera A, Apostolidis A, Andersson KE, et al. An updated systematic review and statistical comparison of standardised mean outcomes for the use of Botulinum toxin in the management of lower urinary tract disorders. Eur Urol 2014;65(5):981-90
22. Aoki KR, Guyer B. Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. Eur J Neurol 2001;8(Suppl 5):21-9
23. Dolly JO, Aoki KR. The structure and mode of action of different botulinum toxins. Eur J Neurol 2006;13(Suppl 4):1-9
24. Pinto R, Lopes T, Silva J, et al. Persistent therapeutic effect of repeated injections of onabotulinum toxin A in refractory bladder pain syndrome/interstitial cystitis. J Urol 2013;189:548-53
25. Smith CP, Radziszewski P, Borkowski A, et al. Botulinum toxin A has antinociceptive effects in treating interstitial cystitis. Urology 2004;64:871-5
26. Graboski CL, Gray DS, Burnham RS. Botulinum toxin A versus bupivacaine trigger point injections for the treatment of myofascial pain syndrome: a randomised double blind crossover study. Pain 2005;118:170-5
27. Jabbari B, Maher N, Difazio MP. Botulinum toxin A improved burning pain and allodynia in two patients with spinal cord pathology. Pain Med 2003;4:206-10
28. Aoki KR. A comparison of the safety margins of Botulinum neurotoxin serotypes A, B, and F in mice. Toxicon 2001;39:1815-20
29. Mangera A, Andersson KE, Apostolidis A, et al. Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA). Eur Urol 2011;60:784-95
30. Chuang YC, Kuo HC, Chancellor MB. Botulinum toxin for the lower urinary tract. BJU Int 2010;105:1046-58
31. Dykstra DD, Sidi AA, Scott AB, et al. Effects of botulinum A toxin on detrusor-sphincter dysenergia in spinal cord injury patients. J Urol 1988;139:919-22
32. Schurch B, Stohrer M, Kramer G, et al. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 2000;164:692-7
33. Giannantoni A, Costantini E, Di Stasi SM, et al. Botulinum A toxin intravesical injections in the treatment of painful bladder syndrome: a pilot study. Eur Urol 2006;49:704-9
34. Russell A, Kavia R, Dasgupta P, Sahai A. The use of botulinum toxin for the treatment of urologic pain. Curr Opin Urol 2013;23:570-8
35. Seth J, Khan MS, Dasgupta P, Sahai A. Botulinum toxin-what urologic uses does the data support? Curr Urol Rep 2013;14:227-34
36. Apostolidis A, Dasgupta P, Fowler CJ. Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol 2006;49:644-50
37. Apostolidis A, Dasgupta P, Denys P, et al. Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur Urol 2009;55:100-9
38. Cruz F, Herschorn S, Aliotta P, et al. Efficacy and safety of onabotulinum toxin-A in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol 2011;60:742-50
39. Rovner E, Kennelly M, Schulte-Baukloh H, et al. Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder. Neurourol Urodyn 2011;30:556-62
40. Chapple C, Sievert KD, MacDiarmid S, et al. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol 2013;64:249-56
41. Smith CP, Chancellor MB. Emerging role of botulinum toxin in the treatment of voiding dysfunction. J Urol 2004;171:2128-37
42. Pinto R, Lopes T, Frias B, et al. Trigonal injection of botulinum toxin A in patients with refractory bladder pain syndrome/interstitial cystitis. Eur Urol 2010;58:360-5
43. Giannantoni A, Porena M, Costantini E, et al. Botulinum A toxin intravesical injection in patients with painful bladder syndrome: 1-year followup. J Urol 2008;179:1031-4
44. Giannantoni A, Cagini R, Del Zingaro M, et al. Botulinum A toxin intravesical injections for painful bladder syndrome: impact upon pain, psychological functioning and quality of life. Curr Drug Deliv 2010;7:442-6
45. Kennelly M, Dmochowski R, Ethans K, et al. Long-term efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: an interim analysis. Urology 2013;81:491-7
46. Kuo HC. Repeated intravesical onabotulinumtoxinA injections are effective in treatment of refractory interstitial cystitis/bladder pain syndrome. Int J Clin Pract 2013;67:427-34
47. Lee CL, Kuo HC. Intravesical botulinum toxin A injections do not benefit patients with ulcer type interstitial cystitis. Pain Physician 2013;16:109-16
48. Kuo HC, Chancellor MB. Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis/painful bladder syndrome. BJU Int 2009;104:657-61
49. Popat R, Apostolidis A, Kalsi V, et al. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol 2005;174:984-8
50. Kuo HC. Preliminary results of suburothelial injection of botulinum a toxin in the treatment of chronic interstitial cystitis. Urol Int 2005;75:170-4
51. Gottsch HP, Miller JL, Yang CC, Berger RE. A pilot study of botulinum toxin for interstitial cystitis/painful bladder syndrome. Neurourol Urodyn 2011;30:93-6
52. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Subcommittee of the International Continence Society. Am J Obstet Gynecol 2002;18:116-26
53. Giannantoni A, Bini V, Dmochowski R, et al. Contemporary management of the painful bladder: a systematic review. Eur Urol 2012;61:29-53